Fed’s Powell opens door to potential rate cuts at Jackson Hole
SAN FRANCISCO—Okupe Oluyemi, the Chief Financial Officer of Hims & Hers Health, Inc. (NYSE:HIMS), recently sold 23,118 shares of the company’s Class A common stock. The shares were sold at an average price of $32.41, resulting in a total transaction value of approximately $749,175.
The transaction, which took place on March 21, 2025, was executed as part of a pre-established Rule 10b5-1 trading plan. Following this sale, Oluyemi retains ownership of 129,248 shares in the company.
The trading plan, adopted on May 31, 2024, allows for the sale of shares at predetermined times and prices, providing a measure of protection to insiders against accusations of insider trading. The shares were sold at varying prices within the range of $32.07 to $32.59.
Hims & Hers Health, known for its telehealth services, continues to operate from its headquarters in San Francisco.
In other recent news, Hims & Hers Health, Inc. has been the focus of several analyst updates and regulatory developments. BofA Securities raised its price target for the company to $22, citing accelerating sales growth in the GLP-1 segment, which now constitutes a significant portion of the company’s online sales revenue. Despite this growth, BofA maintained an Underperform rating, pointing to a potential slowdown in core growth and the risks associated with semaglutide, a key product for the company. The FDA has extended its enforcement discretion for the compounding of semaglutide until April 2025, offering some regulatory certainty for Hims & Hers in the near term.
Meanwhile, Citi reaffirmed its Sell rating with a $27 price target, highlighting ongoing legal proceedings involving tirzepatide, another medication relevant to Hims & Hers’ business. The legal outcome could influence the company’s operations, as the FDA’s removal of tirzepatide from the shortage list impacts its availability. The court’s decision against the Outsourcing Facilities Association’s injunction suggests potential challenges for Hims & Hers if a similar ruling occurs for semaglutide. These developments underscore the regulatory and legal factors currently affecting Hims & Hers, as the company navigates the evolving landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.